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RU (10%). Similar impacts were observed for ES. Based on the real life dataset, a 10% 
decrease DE would lead to a range of reductions across Europe including 16% in 
Denmark, 12% in Austria, 10% in HR and 5% in Netherlands. ConClusions: Price 
reductions of branded therapies in any of the key European markets would likely 
have a significant impact on prices in other markets reducing overall profits for the 
pharmaceutical industry.
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objeCtives: As the result of the 2007 economic crisis, the number of employed 
significantly decreased. In our study we investigated how the number of people 
entitled for sick-pay, the number of days resorting to sick-pay and the number 
of sick-leave days in ratio with one sick-pay case changed in this period regard-
ing age groups and genders. Methods: We used the data of the National Health 
Insurance Fund Administration of Hungary, statistical reports of Nr. OSAP 1514, as 
well as data of Hungarian Central Statistical Office from the period from the years 
between 2005 and 2013. We analysed the number of employees entitled for sick-pay, 
the number of days spent on sick-leave. Results: In the period under investiga-
tion the number of employees entitled for sick-pay increased from 3.486 to 3.796 
thousand people, however, at the same time, the number of sick-pay cases fell 
from 1,252.000 to 825.000, and the number of days spent on sick-leave generally fell 
from 30 to 24. Women spent generally 40-56 percent more days on sick-leave which 
mostly came from childcare. Between the years of 2007 and 2009, people adhering to 
sick-pay were mostly between the ages of 30-34 (28-21%), while from 2010 between 
the ages of 35-39 (20%). This is connected to the number of people employed. From 
2009, the number of employees significantly increase in the age group 55-59 (2008: 
46,2%, 2013:58,4%), and simultaneously the number of people adhering to sick-pay 
also became higher. ConClusions: Based on the comprehensive analysis of the 
statistical data we can ascertain that adhering to sick-pay is in close connection 
with the employment ratio. Furthermore, we can say that in the period after the 
2008 economic crisis the number of days spent on sick-leave fell with 35% and the 
number of days on sick-leave fell with 20%.
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objeCtives: This paper examines the short- and long-run effect of biosimilar entry 
on price erosion. Furthermore, the impact of increases in the number of competi-
tors on prices of originators is investigated. Methods: A series of explanatory 
analyses have been performed using an econometric model which was developed 
for the years 2008–2014 spanning across 10 European countries: Bulgaria, France, 
Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, and the UK. Two 
successful biosimilars were considered for the analyses: filgrastim and epoetins. A 
semi-structured literature review as well as a survey and interviews with country 
experts have been conducted to understand price dynamics in each market. Prices 
were obtained from country experts and verified with IMS Health. The model used 
dynamic panel data analysis, utilising Ordinary Least Squares regression with fixed 
effects, subjected to a Granger causality test. Results: The study assumes that the 
prices of currently marketed biosimilars define the attractiveness of the market and 
impact the entry decision of further competitors. This assumption was confirmed 
for epoetins, where each next biosimilar entrant in the current month leads to a 
7% (p= 0,0001) price decrease next month, with a long-run sustained effect of 4% 
(p= 0,1806). The entrance of new competitors has the highest impact on price erosion 
in Bulgaria, Italy and Poland. There is a strong trend indicating that a doubling in 
the number of competitors leads to about 10% (p= 0,1266) decrease in the originator 
prices in the long-run for filgrastim, with strongest effect in Bulgaria. This effect is 
insignificant for epoetins (p= 0,9694). ConClusions: Biosimilars manufacturers 
should carefully analyse the number of competitors planning to enter the mar-
ket when making strategic decisions on the investment in the development of 
biosimilars.
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objeCtives: In the interest of increasing transparency and access to healthcare 
utilization data, the French government has published the highly anticipated Open 
DAMIR database (Dépenses Assurance Maladie Inter-Régimes). The objective of this 
study was to perform an exploratory analysis of the DAMIR database in order to 
estimate the mean cost of each type of physician visit and the mean surcharge rate 
for technical procedures, by specialty, in order to better inform health economic mod-
eling in the French setting. Methods: The DAMIR database consists of monthly 
extractions of data from the larger French national health insurance limited-access 
database. We analyzed data collected over a 3-month period (September-November 
2014), comprising a total of 98,684,544 outpatient visits and 54,310,532 technical pro-
cedures (including outpatient and inpatient procedures, Diagnosis-Related Group 
billing excepted). Total costs were estimated from the all-payer perspective, in 
accordance with French guidelines. We calculated mean costs for each type of visit, 
including surcharges, and the mean surcharge rate for technical procedures for each 
specialty. Results: The three types of visits associated with the highest mean costs 
were for neurologists (€ 50.58 per visit), surgeons (€ 45.74), and psychiatrists (€ 43.96), 
whereas the lowest mean costs were for general practitioners (€ 24.12), nephrologists 
(€ 25,58), and geriatricians (€ 29.58). The highest surcharge rates for technical proce-
dures were billed by surgeons (mean surcharge of +55.6% of the minimum reimburs-
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objeCtives: To compare technology-specific cost-effectiveness analyses (CEA) 
submitted as part of health technology assessments (HTA) in France, England 
and Canada and to highlight the comments, criticisms and conclusions from the 
HTA agencies in order to assess the feasibility of a unified approach. Methods: 
Newly published health economic appraisals from the French National Authority 
for Health (HAS) were reviewed, analyzed and compared to technology apprais-
als and/or evidence review group (ERG) reports in other countries for the same 
drugs including sofosbuvir (Sovaldi®), trastuzumab emtansine (Kadcyla®), riociguat 
(Adempas®) and dolutegravir (Tivicay®). The analysis focused first on the review 
of methodological approach selected by the manufacturer including model type, 
time horizon, discount rates, perspective, study population, comparators as well as 
efficacy, costs and utility data and presentation of results (i.e. total costs and health 
benefit, incremental cost-effectiveness ratio from both base-case and sensitivity 
analyses). The analysis then focused on comments made by the agency committees, 
criticisms and overall conclusions. For each drug, a comparison between models 
used and agencies’ final recommendations was undertaken to highlight convergent 
and divergent points between countries. Results: Results were heterogeneous 
between drugs which made it difficult to draw a general overarching conclusion. 
Nevertheless, some points were underlined by every agency. As an example, French, 
English and Canadian HTA agencies all drew attention to small patient samples and 
their impacts on the robustness of efficacy data for subgroups in several assess-
ments, which led to uncertainty around estimates of clinical effectiveness and 
therefore cost-effectiveness. ConClusions: Cost-effectiveness analyses have been 
introduced in France as part of the assessment of new health technologies two years 
ago whereas it has been used for about 15 and 20 years in England and Canada 
respectively. This review highlighted the level of similarities between countries 
to assess the feasibility of a unified approach to prepare the submission process.
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objeCtives: Hospital pharmaceutical expenditure dropped by almost 50% after 
memorandum measures were first in place. Severe cuts imposed on targets of phar-
maceutical expenditure between 2012 and 2014, run parallel to a variety of general 
reform measures, affecting primary care and non-hospital access to pharmaceuti-
cals. The aim of this study was to isolate main achievements versus other hospital 
cost-drivers. Methods: End-year 2012-2014 invoiced data from all hospitals in 
Greece were analysed, in order to examine trends in pharmaceutical versus non-
pharmaceutical savings. Non-pharmaceutical savings included costs on appliances, 
orthopaedics and diagnostics. A separate analysis looked at total pharmaceutical 
expenditure versus costs of outsourcing services and other expendables such as 
medical gas and energy supplies. Total expenditure for pharmaceuticals was then 
compared to volumes in unit boxes for the respective years, in order to examine 
effectiveness of other reform measures, other than price erosion and discounts/
rebates offered such as electronic and INN prescribing. Results: Hospital pharma-
ceutical expenditure dropped by 31% over three years, from € 761M in 2012, to € 642M 
in 2013 and € 519M in 2014, when respective savings for orthopaedics, healthcare 
appliances and diagnostics amounting to 6%, 25% and 13% respectively (cumulative 
2014 was € 508M). Total savings due to outsourcing services and medical and energy 
supplies reached (-)26% and (-)20% respectively, with an absolute sum of € 180M over 
the three years. Regarding volumes of hospital lines for the three respective years, 
unit numbers dropped from 84,525,999, to 79,987,535 and 77,075,298 unit-boxes. 
When calculating pharmaceutical costs, hospitals spent on average € 9.00, € 8.02 and 
€ 6.74 per unit used in 2012, 2013 and 2014 respectively. ConClusions: Significant 
savings have been achieved for pharmaceuticals in the Greek hospital setting. The 
cuts were mainly attributable to improved cost/pack ratio, but a notable decrease in 
units was also observed. Percentage savings in pharmaceuticals were higher than 
respective savings achieved in other hospital cost-drivers.
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objeCtives: International Reference Pricing (IRP) is a key cost-containment method 
for health care payers. We have developed based on local experts and publically 
available IRP rules a user-friendly price management tool (Orange) designed 
to enable the real-time forecasting of the global pricing impact of a branded 
launched product price change in a single market. The objective of this analysis is 
to explore, using Orange, the potential impact of price reductions in key EU mar-
kets. Methods: Two price datasets were used to illustrate core features of the 
Orange tool. In the first all prices were set at € 10 and in the second (real life dataset) 
prices were in the range of € 1.78-2.86 (highest for UK followed by DE, ES, IT and FR). 
With each dataset prices were varied for Germany (DE), UK, France (FR), Spain (ES) 
and Italy (IT). Results: A DE price decrease would result in the greatest number of 
reductions elsewhere. A 10% decrease in DE (on € 10) would lead to the same % reduc-
tion in FR, Romania (RO), Russia (RU), Slovenia (SI), Croatia (HR) and Luxembourg (LU) 
and smaller reductions in multiple other countries. A 10% reduction in UK would 
lead mainly to a 10% decrease in FR, RO and HR. A 10% price reduction in FR would 
have greatest impact in HR (13%), SI and RU (10%) and in IT it would be FR, RO and 
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mended threshold of willingness-to-pay (£20,000 per QALY) in conjunction with 
the costs of each route to report the incremental net monetary benefits (INB) of 
nutritional support via PN versus EN. Results: Mean QoL at 90-days and one year 
was similar between the randomised groups. At one year, the PN group had higher 
costs (£1,580 [95% CI -£792 to £3,951]), similar QALYs (0.013 [95% CI -0.014 to 0.040]) 
and negative INB (-£1,320 [95% CI -£3,709 to £1,069]) compared to the EN group. 
When a lifetime time horizon is taken, the INB of PN was positive but with con-
siderable uncertainty surrounding the result (£440 [95% CI -£3,586 to £4,466]). The 
probabilities that PN is more cost effective were 14% (1 year) and 58% (lifetime), 
respectively. ConClusions: For critically ill adult patients, providing nutritional 
support via PN versus EN is unlikely to be cost-effective. However, it should be 
recognised that considerable uncertainty surrounds the cost-effectiveness results, 
especially when projected over the patient’s lifetime.
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objeCtives: Japanese government is now trying to introduce cost-effectiveness 
analysis into its healthcare system because of severe budget constraint. It would 
be important to elucidate the basic attitude of physicians towards health care 
resource allocation on this occasion. Methods: A web-based survey for physi-
cians was carried out in Japan, adjusting for age, sex, specialty, and hospital scale, 
between February and March in 2015. The questionnaire consisted of two main 
inquiries and related questions. The 1st question was about medical decision to 
choose between two screening test for a population at low risk for colon cancer. 
Test A was more cost effective than test B, but was too expensive to be given to 
everyone in the population. The option 1 was that all subjects received test B and 
subsequently the death of 1,000 people was prevented, while the option 2 was that 
a half of the subjects were selected by lottery and received test A, preventing the 
death of 1,100 people as a consequence. The 2ndquestion was concerning prior-
ity setting between two types of diseases differing the treatment cost(disease A: 
¥10 million per patient; disease B: ¥2 million per patient). The physicians were 
asked to choose some possible combinations of numbers of people treated if the 
total expenditure were limited to 100 million yen. Results: Out of 1,089(male/
female= 891/198) respondents, 699 chose the option 1 in the 1st question. In 
question 2, 187 chose the least utilitarian combination(A;8, B;10), 125 chose 2nd 
combination(A;6, B;20), 277 chose 3rd one(A;4, B;30), 76 chose 4thone(A;2, B;40), and 
424 chose the most utilitarian option(A;0, B;50). ConClusions: We investigated 
the basic attitude of physicians towards healthcare resource allocation in Japan 
in a setting of budget constraints, which revealed that fairly extreme utilitarian 
selection was the more popular among them than expected.
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objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when wholesal-
ers were also authorized, pharmaceuticals under this status could only be imported 
by the Turkish Pharmacists’ Association (TPA). The aim of this study is to understand 
the trends in unlicensed medicine consumption between 2011 and 2013 when the 
TPA was the only authorized supplier. Methods: Consumption data of the top 100 
imported unlicensed medicines with the highest sales share in total expenses of 
imported off-label use was taken from the TMMDA computer database. Descriptive 
analysis was conducted. Results: The analysis showed that cost of the top 100 
imported unlicensed medicines increased in every year from 232 billion TL to 747 
billion TL between 2011 and 2013, respectively. According to the ATC code, L group 
(Antineoplastic and immunomodulating agents) had the highest number of active 
ingredients in top 100. In addition to this, the number of L group medicines rose from 
37 to 55 between 2011 and 2013. Also the average cost per box increased from 2.837 
TL to 5.308 TL in the same period. ConClusions: The cost of imported unlicensed 
medicines use increased every year in Turkey. Some cost-containment measures 
(especially for antineoplastic medicines) should be taken to reduce this cost without 
risking the patients’ access to innovative medicines.
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objeCtives: To determine the disease focus of all papers indexed in the PubMed 
database that reported costs or resource use as an outcome and were published 
in 2014. Methods: An evidence surveillance process was established based on a 
systematic search of PubMed, using key words relevant to the costs or resource use 
associated with healthcare or disease and limited to studies published in English, 
in humans, with abstracts, and either clinical trials or observational, comparative 
or multicentre studies. The surveillance incorporated all studies published from 
2010 and was updated weekly. Abstracts identified by the search of studies that 
reported data on economic burden outcomes were indexed according to disease 
area, using the chapter categorisation from ICD-10 as a framework. To account 
able fee for a given procedure) and obstetricians/gynecologists (+31.9%), while the 
lowest rates of surcharges were billed by nephrologists (< +1%) and pulmonologists 
(+3.0%). ConClusions: This study confirms that Open DAMIR data can provide a 
more nuanced estimation of the cost of certain care services than is commonly used 
for health economic evaluation in France. While the publication of this database 
represents a step forward, the inclusion of select additional variables to the database 
would further increase its usefulness in health economic assessment.
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objeCtives: Entering the fiscal adjustment program in 2010, one of the primary 
mandates for Greece was to reduce public pharmaceutical expenditure from the then 
current 2.2% of GDP to 1%. Within this context, a series of policies (increased copay-
ments, price-cuts, delisting, rebates, clawbacks etc) were enforced. As a result, 2014 
public pharmaceutical expenditure did reach 1% of GDP, but following a significant 
increase in private spending. In this light, the purpose of this study is to investigate 
the macroeconomic trends in pharma expenditure during 2009-2014 and estimate 
the public/private mix of contributions. Methods: Aggregate data on outpatient 
sales by the Greek National Medicines Agency for 2009-2014, formed the basis of the 
analysis. To account for price changes, expenditures were adjusted to 2014 constant 
prices, by estimating and using the weighted average price/box for 2014 as deflator. 
Expenditures were allocated to public or private payers according to official macro-
economic reports of the third-party payers for 2009 and via publicly available subac-
counts for 2014. Results: Pharmaceutical expenditure totaled 6.12 billion euros in 
2009 (€ 5.1 billion public, € 0.09 billion rebates, € 0.91 billion private) and € 3.57 billion 
in 2014 (€ 2 billion public expenditure, € 428 million in rebates/clawbacks, € 1.14 billion 
private). Average price per box sold fell by 36.2% during 2009-2014. Thus, when adjust-
ing for prices, the respective figures are € 3.90 and € 3.57 billion. Public/private mix was 
85%/15% for 2009 and 64%/36% for 2014 (excluding rebates). A total of a € 0.93 billion 
shift towards patients and companies (€ 564million towards patients and € 366million 
as additional rebates/clawbacks) resulted in achieving the fiscal target of 1% of GDP 
for 2014 public pharma expenditure. ConClusions: Despite the rhetoric and the 
reforms implemented, total outpatient pharmaceutical volumes dropped by only 8% 
during 2009-2014. Fiscal adjustment was achieved by cost-shifting to private payers, 
primarily to patients, raising concerns about equity in access and social solidarity.
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objeCtives: To study the direct costs of drug-related morbidity using three 
sources of data; experts opinion, medical records and survey responses from the 
general public. Methods: Probabilities for clinical outcomes of drug-related mor-
bidity were estimated based on expert opinions from 29 pharmacists and 19 phy-
sicians. Costs were assigned using Cost Per Patient register data to resource-use 
from drug-related morbidity identified in the medical records of 4970 randomly 
selected individuals from a Swedish county during a three-month study period. A 
postal survey was sent to a random sample of the Swedish population. Resource-
use resulting from drug-related morbidity reported during one month by 7099 
survey respondents, and by the expert panels, were assigned unit costs based 
on national costs statistics. All cost estimates were prevalence-based. Results: 
The expert panels reported drug-related morbidity to be common, and to cause 
considerable healthcare resource use representing up to 20% of all costs to the 
healthcare system. Drug-related morbidity identified in medical records were 
estimated to cause 1.5% of all drug costs and 9.5% of healthcare costs, and costs 
occurred in all parts of the healthcare system. According to survey responses, two 
types of drug-related morbidity - adverse drug reactions and sub-therapeutic effect 
of medication therapy - caused 0.5% of all drug costs and 6.1% of all healthcare 
costs. In addition, respondents reported informal care, lost leisure time, and sick-
leave resulting from drug-related morbidity which were unfeasible to assign costs 
in these studies. ConClusions: Based on these results, drug-related morbidity 
causes considerable resource use and harm in the general public, and throughout 
the healthcare system; in primary care, other outpatient care and inpatient care. 
Moreover, it appears that there are additional resource use due to drug-related 
morbidity, such as productivity loss, which should be included for a full account 
of the economic impact of drug-related morbidity.
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objeCtives: Early and appropriate nutritional support is recommended for criti-
cally ill patients. Evidence is conflicting regarding the optimum route of deliv-
ery and robust cost-effectiveness evidence is lacking. The objective of the study 
was to evaluate the cost-effectiveness of early nutritional support via the par-
enteral (PN) versus the enteral (EN) route in critically ill adults. Methods: We 
undertook a cost-effectiveness analysis (CEA) using data from a large, pragmatic, 
multi-centre RCT that recruited patients from 33 English adult, general critical 
care units. Resource use and outcome data on 2388 trial patients were used to 
report cost-effectiveness at 90-days and at one year, and to project lifetime cost-
effectiveness. The CEA used information on Health-related Quality of Life (QoL) 
at 90-days and at one year combined with information on vital status to report 
Quality-Adjusted Life Years (QALYs). Each QALY was valued using the NICE recom-
